DePuy Synthes, a subsidiary of Johnson & Johnson (NYSE:JNJ), announced an exclusive distribution agreement with CGBIO for the bone graft substitute NOVOSIS across the United States, Canada and Australia.
NOVOSIS designed for multiple orthopaedic applications
NOVOSIS is a growth factor-based bone graft substitute intended for use in a range of orthopaedic procedures, including spinal surgery, craniomaxillofacial procedures and trauma-related applications.
The product is currently being evaluated in the United States through an investigational device exemption study focused on spinal procedures to assess both safety and clinical effectiveness.
Agreement expands existing partnership between companies
Under the terms of the deal, DePuy Synthes receives exclusive distribution rights for NOVOSIS in the three designated markets, along with rights of first negotiation for potential expansion into additional global territories.
The latest agreement builds on an earlier partnership signed in February 2025, which granted Johnson & Johnson and DePuy Synthes distribution rights for the product in Korea, Taiwan, Thailand, India, Hong Kong and Macau.
DePuy Synthes strengthens regenerative medicine portfolio
“This collaboration reflects our continued focus on strengthening our portfolio with differentiated technologies that address unmet needs and support patient care,” said Namal Nawana, Worldwide President of DePuy Synthes.
CGBIO specializes in regenerative medicine technologies, and the addition of NOVOSIS further expands DePuy Synthes’ orthopaedics portfolio, which already includes products for joint reconstruction, trauma care, spinal surgery and sports medicine.
Commercial launch remains subject to approvals
The companies said future commercialization of NOVOSIS will depend on the outcome of clinical studies and receipt of the necessary regulatory approvals.
The announcement was disclosed through a company press release.